ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/non-small-cell-lung/adjuvant-neoadjuvant
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Respiratory / Non small cell lung - Adjuvant/neoadjuvant
13
trial(s) found.
NCT07554339
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) (
1084-015
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-L1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
NCT07513376
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (
INTerpath-014
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT07431827
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (
KANDLELIT-013
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT07195695
Curative
Phase 3
Recruiting
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations (
1479-0032
)
ERBB2 inhibitor,second generation
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06890598
Curative
Phase 3
Recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
SUNRAY-02
KRAS G12C inhibitor,OFF-state inhibitor
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06312137
Curative
Phase 3
Recruiting
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (
TroFuse-019
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06284317
Curative
Phase 3
Recruiting
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC (
ADOPT-lung
)
anti-PD-L1 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06077760
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (
INTerpath-002
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - New Zealand Clinical Research
ACTRN12625001151426
Curative
Not Applicable
Recruiting
Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy (
HD-PRiMe
)
radiotherapy
Bladder cancer
Cancer
Colorectal cancer
Cutaneous squamous cell carcinoma
Head and neck cancer
Non-small cell lung cancer
Oesophageal cancer
Pancreatic cancer
Skin cancer
Triple-negative breast cancer
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12608000061336
Curative
Phase 2
Not yet recruiting
A randomised phase II study comparing cisplatin and docetaxel with or without cetuximab given as neoadjuvant therapy in patients with stage II and IIIA resectable non-small cell lung cancer. (
ANTS
)
anti-EGFR monoclonal antibody
platinum-based antineoplastic agent
taxane
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
ACTRN12606000202561
Curative
Recruiting
A randomised controlled trial of Docetaxel plus Carboplatin as neo-adjuvant versus adjuvant chemotherapy treatment in stage IB to IIIA non-small cell lung cancer (NSCLC) to improve disease free survival
platinum-based antineoplastic agent
taxane
Non-small cell lung cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (1)
Recruitment Country and State
NSW (9)
QLD (8)
WA (8)
VIC (8)
SA (4)
NZ (3)
TAS (1)
Phase
Phase 2 (2)
Phase 3 (9)
Trial Type
Curative (13)
Cancer Therapy Class
PD-1/PD-L1
69%
PD-1
54%
PD-L1
31%
KRAS
23%
EGFR
15%
ERBB2
8%
Trop2
8%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
6009 - Nedlands - One Clinical Research (3)
5042 - Bedford Park - Flinders Medical Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2086 - Frenchs Forest - Northern Beaches Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4215 - Southport - Tasman Oncology (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
7000 - Hobart - Royal Hobart Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
NZ.8011 - Christchurch - New Zealand Clinical Research (1)
2170 - Liverpool - Liverpool Hospital (1)
3066 - Epping - Northern Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
Cancer Type
Cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Solid tumour
Thoracic cancer
Bladder cancer
Breast adenocarcinoma
Breast cancer
Colorectal cancer
Cutaneous squamous cell carcinoma
Gastroesophageal cancer
Gastrointestinal cancer
Head and neck cancer
Lower gastrointestinal cancer
Non-melanoma skin cancer
Oesophageal cancer
Pancreatic cancer
Pancreatobiliary cancer
Skin cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
Urogenital cancer
EGFR-mutant non-small cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy